Parker, Waichman, Alonso LLP

YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

US FDA issues warning on Schering's MS drug Campath

Dec 1, 2005 | AFX

The US Food and Drug Administration has issued a warning on the use of Schering AG's multiple sclerosis drug Campath.

The FDA said three patients in a clinical study on the drug developed severe idiopathic thrombocytopenic purpura (ITP), a rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding.

One of the patients died, the FDA said.

Campath is so far not approved to treat MS. It is only approved for treating a form of blood cancer called B-cell chronic lymphocytic leukemia (B-CLL).

The label for Campath has a warning about serious and rare blood problems that may occur with the use of this medicine.

Schering could not be reached for comment.

Campath

* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Mailing Address
(include Apt/Suite information)

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

News Feeds

WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS

XML

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising